Skip to main content

Table 2 Associations of FBXOs expression with clinical manifestations in BC patients (Bc-GenExMiner, v4.4)

From: Systematic analysis of the expression and prognosis relevance of FBXO family reveals the significance of FBXO1 in human breast cancer

Variables

No

FBXO1

P-value

FBXO2

P-value

FBXO5

P-value

FBXO6

P-value

FBXO16

P-value

FBXO17

P-value

FBXO22

P-value

FBXO28

P-value

FBXO31

P-value

FBXO45

P-value

Age

 ≤ 51

1099

****

p =  .0515

****

p =  .7262

p =  .7978

***

p =  .6565

p =  .6215

**

****

 > 51

3208

 

 

 

  

Nodal status

 –

2415

 

***

p =  .6545

p =  .2297

p =  .1867

p =  .2105

p =  .3476

 

****

 

*

p =  .2323

 

*

 + 

1646

ER(IHC)

 –

551

****

 

****

****

**

 

****

****

*

 

***

p =  .2564

****

 + 

3911

 

  

  

 

PR(IHC)

 –

828

****

 

****

****

p =  .2212

 

****

*

p =  .1015

p =  .4141

p =  .4587

****

 + 

3498

 

 

 

 

HER2(IHC)

 –

3582

 

****

****

 

****

p =  .4834

****

****

p =  .5320

p =  .2814

****

 

****

 + 

661

 

  

 

Basal-like statues

 Basal-like

832

****

 

**

****

***

 

****

****

p =  .2002

 

***

*

****

 Not

3836

 

  

 

  

Triple-negative statues(IHC)

 TNBC

317

****

 

****

****

p =  .4260

 

****

****

*

 

**

p =  .7470

****

 Not

4119

 

 

  

 

P53 status (sequence-based)

 Wild type

699

 

****

***

 

****

p =  .2017

****

 

***

p =  .7978

p =  .6453

p =  .0796

 

****

 Mutated

328

 

 

SBR

 SBR1

544

SBR2 > SBR1

****

SBR3 < SBR1

****

SBR3 > SBR1

****

SBR3 > SBR1

****

SBR2 < SBR1

****

SBR2 < SBR1

****

SBR3 > SBR1

****

p =  .0730

SBR3 < SBR1

****

SBR2 > SBR1

****

 SBR2

1699

SBR3 > SBR1

****

SBR3 < SBR2

****

SBR3 > SBR2

****

SBR3 > SBR2

****

SBR3 < SBR1

****

SBR3 < SBR1

****

SBR2 > SBR1

*

SBR3 < SBR2

****

SBR3 > SBR1

****

 SBR3

1374

SBR3 > SBR2

****

SBR2 = SBR1

SBR2 > SBR1

****

SBR2 > SBR1

**

SBR3 < SBR2

****

SBR3 < SBR2

**

SBR3 > SBR2

*

SBR2 < SBR1

***

SBR3 > SBR2

****

TPI

 NPI1

1173

NPI2 > NPI1

****

NPI2 < NPI1

*

NPI2 > NPI1

****

NPI2 > NPI1

****

NPI2 < NPI1

****

NPI2 < NPI1

****

NPI3 > NPI1

****

NPI3 > NPI1

*

NPI2 < NPI1

****

NPI2 > NPI1

****

 NPI2

1525

NPI3 > NPI1

****

NPI3 < NPI1

*

NPI3 > NPI1

****

NPI3 > NPI1

****

NPI3 < NPI1

****

NPI3 < NPI1

****

NPI3 > NPI2

**

NPI2 = NPI1

NPI3 < NPI1

****

NPI3 > NPI1

****

 NPI3

416

NPI3 > NPI2

****

NPI3 = NPI2

NPI3 > NPI2

**

NPI3 > NPI2

*

NPI3 = NPI2

NPI3 = NPI2

NPI2 > NPI1

*

NPI3 = NPI2

NPI3 < NPI2

**

NPI3 > NPI2

***

  1. ↑, upregulated; –, no significant difference; No., number of patients enrolled; ER, oestrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; IHC, immunohistochemistry; SBR, Scarff-Bloom-Richardson grade; NPI, Nottingham prognostic index
  2. *P < 0.05; **P < 0.01; *** P < 0.001; ****P < 0.0001